Bruker (NASDAQ:BRKR) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Bruker (NASDAQ:BRKR) released its quarterly earnings results on Tuesday. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11, Zacks reports. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. During the same quarter last year, the company posted $0.32 EPS. Bruker’s revenue for the quarter was up 5.2% on a year-over-year basis. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• Positive Sentiment: Bruker returned to organic revenue growth in Q2, with revenue up 5.2% year over year and organic bookings growth of 10%; biopharma bookings rose more than 20%, while semiconductor metrology and energy research orders grew more than 50%.
• Positive Sentiment: Cost reductions, favorable mix and volume drove a 510-basis-point increase in non-GAAP operating margin to 14.1%, while non-GAAP EPS rose 53% to $0.49. The company remains on track for $140 million in annualized 2026 savings and expects an additional $20 million of savings from its new operating structure in 2027.
• Positive Sentiment: Management reiterated its 2026 outlook, including 1%-2% organic revenue growth, 250-300 basis points of operating-margin expansion and non-GAAP EPS of $2.10-$2.15, representing 15%-17% growth. Executives also expect further margin expansion and double-digit EPS growth in 2027.
• Negative Sentiment: U.S. academic and government demand remained weak, contributing to a more than $15 million year-over-year revenue decline in that market during Q2, while Asia-Pacific revenue fell by low double digits. A $135 million non-cash goodwill impairment tied to the loss-making automation and spatial biology businesses resulted in a GAAP diluted loss of $0.41 per share.
• Neutral Sentiment: About $20 million of semiconductor revenue is shifting from Q3 into Q4 due to customer delivery requirements, leading management to expect Q3 organic revenue to be roughly flat to slightly up and sequentially lower margins and EPS. The company expects a significantly stronger Q4, supported by semiconductor deliveries, an ultra-high-field system and improved volume and mix.

Bruker Stock Up 4.9%

Shares of NASDAQ:BRKR traded up $2.44 during midday trading on Wednesday, hitting $52.74. 3,367,047 shares of the stock were exchanged, compared to its average volume of 2,420,349. The company has a market capitalization of $8.03 billion, a PE ratio of -220.09, a P/E/G ratio of 2.06 and a beta of 1.28. Bruker has a 52-week low of $28.53 and a 52-week high of $65.30. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The business’s fifty day simple moving average is $58.59 and its two-hundred day simple moving average is $46.71.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

Trending Headlines about Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported second-quarter adjusted earnings of $0.49 per share, well above the $0.38 analyst consensus and up from $0.32 a year earlier. The earnings beat and stronger margins provide support for the stock. Bruker Q2 Earnings Beat Estimates
• Positive Sentiment: Management maintained fiscal 2026 adjusted EPS guidance of $2.10 to $2.15, broadly in line with the $2.12 consensus. The earnings outlook was not reduced despite the revenue guidance adjustment. Bruker Corporation Earnings Call Highlights Margin Strength
• Neutral Sentiment: Second-quarter revenue increased 5.2% year over year to $838.5 million, but missed the $853.6 million analyst estimate. The mixed result helps explain investor caution even as earnings exceeded expectations. Bruker Q2 Earnings Snapshot
• Negative Sentiment: Bruker lowered its fiscal 2026 reported revenue guidance to approximately $3.54 billion-$3.57 billion from $3.57 billion-$3.60 billion. Management attributed the change primarily to foreign exchange and tax assumptions, but investors remain focused on slower growth in the company’s core markets. Weak Growth in Its Primary Market Continues to Weigh Heavily on Bruker Shares
• Negative Sentiment: About $20 million of revenue is expected to shift from the third quarter into the fourth quarter because of semiconductor-customer delivery timing, creating a weaker near-term revenue profile. Bruker also recorded a $134.9 million non-cash goodwill impairment, resulting in a GAAP loss for the quarter. Bruker Revenue Outlook and Q3 Timing Shift

Analysts Set New Price Targets

BRKR has been the subject of a number of analyst reports. Wolfe Research assumed coverage on shares of Bruker in a research note on Monday, June 1st. They set a “peer perform” rating for the company. Citigroup cut their price target on shares of Bruker from $60.00 to $53.00 and set a “neutral” rating on the stock in a report on Wednesday. TD Cowen restated a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. JPMorgan Chase & Co. lifted their price objective on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Finally, Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $56.64.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BRKR. Allworth Financial LP lifted its holdings in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares during the last quarter. Federated Hermes Inc. increased its holdings in Bruker by 6.7% in the fourth quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock worth $284,000 after buying an additional 380 shares during the last quarter. Parallel Advisors LLC increased its holdings in Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after buying an additional 479 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Bruker during the fourth quarter valued at approximately $26,000. Finally, UMB Bank n.a. lifted its stake in Bruker by 57.9% in the fourth quarter. UMB Bank n.a. now owns 1,571 shares of the medical research company’s stock valued at $74,000 after acquiring an additional 576 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.